Patents by Inventor Kevin Andrew McDonnell

Kevin Andrew McDonnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic Nanoparticles Having EGFR Ligands and Methods of Making and Using Same
    Publication number: 20190029960
    Abstract: Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer-EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.
    Type: Application
    Filed: October 12, 2018
    Publication date: January 31, 2019
    Applicant: Pfizer Inc.
    Inventors: Stephen E. Zale, Kevin Andrew McDonnell, Allen Thomas Horhota
  • Therapeutic nanoparticles having EGFR ligands and methods of making and using same
    Patent number: 10137088
    Abstract: Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer—EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: November 27, 2018
    Assignee: Pfizer Inc.
    Inventors: Stephen E. Zale, Kevin Andrew McDonnell, Allen Thomas Horhota